• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioAge Labs, Inc. - Common Stock (NQ:BIOA)

    10.78 +1.74 (+19.25%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,520,198
    Open 9.500
    Bid (Size) 10.50 (100)
    Ask (Size) 10.96 (100)
    Prev. Close 9.040
    Today's Range 9.180 - 10.96
    52wk Range 4.120 - 25.95
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Top movers in Friday's session ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill

    Performance

    YTD
    -16.0%
    -16.0%
    1 Month
    -56.6%
    -56.6%
    3 Month
    -35.1%
    -35.1%
    6 Month
    -46.4%
    -46.4%
    1 Year
    +143.9%
    +143.9%

    More News

    Read More
    Gapping stocks in Friday's session ↗
    Via Chartmill
    Friday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease ↗
    Via MarketBeat
    News headline image
    BioAge Labs to Present at Upcoming Investor Conferences
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
    Via FinancialNewsMedia
    News headline image
    A Healthcare Fund Just Made Bitgo Its Biggest Bet ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗
    Via MarketBeat
    News headline image
    BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Announces Pricing of Upsized $115.0 Million Public Offering
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Announces Proposed Public Offering
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
    From BioAge Labs, Inc.
    Via GlobeNewswire
    Tuesday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole ↗
    Via The Motley Fool
    News headline image
    BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs to Present at Jefferies Global Healthcare Conference in London
    From BioAge Labs, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is BioAge Labs, Inc. - Common Stock publicly traded?
    Yes, BioAge Labs, Inc. - Common Stock is publicly traded.
    What exchange does BioAge Labs, Inc. - Common Stock trade on?
    BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for BioAge Labs, Inc. - Common Stock?
    The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market
    What is the current price of BioAge Labs, Inc. - Common Stock?
    The current price of BioAge Labs, Inc. - Common Stock is 10.78
    When was BioAge Labs, Inc. - Common Stock last traded?
    The last trade of BioAge Labs, Inc. - Common Stock was at 08/03/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.